ACE2 and inflammatory bowel disease: In conclusion, individuals with IBD do not exhibit molecular changes in tissular or circulating ACE2 nor TMPRSS2 consistent with increased vulnerability to SARS-CoV-2 coronavirus cell entry in the gastrointestinal tract.